Soon after the publication of the synthetic lethality of PARP inhibitors and HR deficiency, Rottenberg and colleagues explored the use of PARP inhibitors for cancer treatment in vivo using a Brca1 mouse model of breast tumors [174]. This evidence concerns the gene BRCA1 and breast neoplasm.